Revenue from Contracts with Customers (Tables)

9 Months Ended

Sep. 30, 2018

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The following table provides information about disaggregated revenue by major product line and primary geographic market (in thousands):

	Three Months Ended September 30, 2018								Nine Months Ended September 30, 2018
	Americas		Europe and Middle East		Asia Pacific		Total		Americas		Europe and Middle East		Asia Pacific		Total
Product revenue:
Instruments	$	3,696	$	1,149	$	584	$	5,429	$	9,512	$	4,189	$	1,890	$	15,591
Consumables	7,808		2,633		699		11,140		20,770		7,882		2,126		30,778
In vitro diagnostic kits	783		1,687		77		2,547		2,382		4,600		252		7,234
Total product revenue	12,287		5,469		1,360		19,116		32,664		16,671		4,268		53,603
Service revenue	1,582		641		114		2,337		4,383		1,589		307		6,279
Total product and service revenue	13,869		6,110		1,474		21,453		37,047		18,260		4,575		59,882
Collaboration revenue	7,163		—		—		7,163		16,818		—		—		16,818
Total revenues	$	21,032	$	6,110	$	1,474	$	28,616	$	53,865	$	18,260	$	4,575	$	76,700

	Three Months Ended September 30, 2017								Nine Months Ended September 30, 2017
	Americas		Europe and Middle East		Asia Pacific		Total		Americas		Europe and Middle East		Asia Pacific		Total
Product revenue:
Instruments	$	1,760	$	1,392	$	1,292	$	4,444	$	7,603	$	4,231	$	3,115	$	14,949
Consumables	6,146		2,283		591		9,020		18,265		6,481		2,060		26,806
In vitro diagnostic kits	705		869		115		1,689		1,883		2,890		190		4,963
Total product revenue	8,611		4,544		1,998		15,153		27,751		13,602		5,365		46,718
Service revenue	1,348		367		47		1,762		3,179		962		131		4,272
Total product and service revenue	9,959		4,911		2,045		16,915		30,930		14,564		5,496		50,990
Collaboration revenue	10,101		—		—		10,101		28,682		—		—		28,682
Total revenues	$	20,060	$	4,911	$	2,045	$	27,016	$	59,612	$	14,564	$	5,496	$	79,672

Schedule of New Accounting Pronouncements and Changes in Accounting Principles

In accordance with the new revenue guidance, the disclosure of the impact of adoption of this new standard to our condensed consolidated statements of operations and balance sheets was as follows:

	Three Months Ended September 30, 2018								Nine Months Ended September 30, 2018
(in thousands, except per share amounts)	As Reported			Amounts under previous revenue standard			Effect of Change		As Reported			Amounts under previous revenue standard			Effect of Change
Revenue:
Product and service	$	21,453		$	21,272		$	181	$	59,882		$	59,303		$	579
Collaboration	7,163			7,163			—		16,818			16,818			—
Total revenue	28,616			28,435			181		76,700			76,121			579
Net loss	$	(16,486	)	$	(16,667	)	$	181	$	(56,290	)	$	(56,869	)	$	579
Net loss per share - basic and diluted	$	(0.56	)	$	(0.57	)	$	0.01	$	(2.09	)	$	(2.11	)	$	0.02

	September 30, 2018
(in thousands)	As Reported			Balances under previous revenue standard			Effect of Change
Liabilities:
Deferred revenue, current portion	$	8,905		$	8,730		$	175
Stockholders' equity
Accumulated deficit	$	(370,146	)	$	(369,971	)	$	(175	)